In Vivo CRO Market Size To Reach $7.93 Billion By 2030

In Vivo CRO Market Growth & Trends

The global in vivo CRO market size is expected to reach USD 7.93 billion by 2030, registering a CAGR of 8.1% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

 Request a free sample copy or view report summary: In Vivo CRO Market Report

In Vivo CRO Market Report Highlights

• The rodent-based segment held the largest revenue share of 81.8% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research

• The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth

• The oncology segment dominated the market in 2023, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications

• The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth

• The GLP toxicology segment accounted for the largest market share in 2023 owing to the increasing number of standardized studies conducted according to specific guidelines

• North America held the largest revenue share of 50.0% in in-vivo CRO market in 2023. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

In Vivo CRO Market Segmentation

Grand View Research has segmented the global in vivo CRO market based on model type, modality, indication, GLP type, and region:

In Vivo CRO Model Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Rodent based

  • Rat Models

  • Mice Models

  • Others

• Non-Rodent based

In Vivo CRO Modality Outlook (Revenue, USD Billion, 2018 - 2030)

• Small Molecules

• Large Molecules

  • Cell & Gene Therapy

    • CAR T-cell therapies

    • CAR-NK cell therapy

    • TCR-T cell therapy

    • Other (Includes- TCR-NK, CARM, and TAC-T)

  • RNA Therapy

  • Others

In Vivo CRO Indication Outlook (Revenue, USD Billion, 2018 - 2030)

• Oncology

  • Blood cancer

  • Solid tumor

    • Syngeneic model

    • Patient derived xenograft

    • Xenograft

  • Others

• CNS Conditions

  • Epilepsy

  • Parkinson's disease

  • Huntington's disease

  • Stroke

  • Muscular Dystrophy

  • Alzheimer’s Disease

  • Traumatic brain injury

  • Amyotrophic lateral sclerosis (ALS)

  • Spinal Muscular Atrophy

  • Muscle regeneration

  • Other Neurodevelopment Disorders

• Diabetes

• Obesity

• Pain management

  • Chronic pain

  • Acute pain

• Autoimmune/inflammation conditions

  • Rheumatoid Arthritis

  • Multiple Sclerosis

  • Osteoarthritis

  • Irritable Bowel Syndrome

  • Others

• Others

In Vivo CRO GLP Type Outlook (Revenue, USD Billion, 2018 - 2030)

• GLP Toxicology

• Non GLP

In Vivo CRO Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the In Vivo CRO Market

• IQVIA Inc.

• Crown Bioscience

• Taconic Biosciences, Inc.

• PsychoGenics Inc.

• Evotec

• Janvier Labs

• Biocytogen Boston Corp

• GemPharmatech

• Charles River Laboratories

• Icon Plc

• Labcorp Drug Development

• Parexel International Corporation

• SMO Clinical Research (I) Pvt Ltd.